Literature DB >> 28025383

Association of the combination of time-weighted variability of tacrolimus blood level and exposure to low drug levels with graft survival after kidney transplantation.

Benaya Rozen-Zvi1,2, Shira Schneider1,2, Shelly Lichtenberg1,2, Hefziba Green2,3, Ori Cohen2,4, Uzi Gafter2, Avry Chagnac1,2, Eytan Mor2,5, Ruth Rahamimov1,2,5.   

Abstract

Background: The variability of tacrolimus blood levels has been shown to be associated with inferior graft survival. However, the effect of variability during the early post-transplantation period has not been evaluated. We sought to evaluate the association between time-weighted variability in the early post-transplantation period and graft survival. We also explored the interaction between drug level variability and exposure to inadequate drug levels.
Methods: This retrospective cohort study included all patients who underwent kidney transplantation in the Rabin Medical Center and were treated with tacrolimus. Time-weighted coefficient of variability (TWCV) was defined as time-weighted standard deviation divided by the mean drug level. Univariate and multivariate Cox proportional hazard model was used with the primary outcome of patients and graft survival.
Results: The study population included 803 patients who underwent kidney transplantation between 1 January 2000 and 29 September 2013. The high tertile of TWCV of tacrolimus blood levels was associated with reduced graft survival by univariate and multivariate analyses [hazard ratio (HR) 1.69, 95% confidence interval (CI) 1.14-2.53, P = 0.01 and HR 1.74, 95% CI 1.14-2.63, P = 0.01, respectively]. The interaction between high TWCV and exposure to inadequately low drug levels was significantly associated with reduced survival (P = 0.004), while the interaction between TWCV and high drug blood levels was not. One hundred and thirty patients (16.2%) had the combination of high TWCV and exposure to low drug values (<5 ng/mL). These patients had reduced graft survival by univariate and multivariate analyses (HR 2.42, 95% CI 1.57-3.74, P < 0.001 and HR 2.6, 95% CI 1.65-4.11, P < 0.001, respectively). Conclusions: The combination of high TWCV and exposure to low drug levels might identify high-risk patients in the early post-transplantation period.
© The Author 2016. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  graft survival; immunosuppression; kidney transplantation; variability

Mesh:

Substances:

Year:  2017        PMID: 28025383     DOI: 10.1093/ndt/gfw394

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  10 in total

1.  Tacrolimus Variability: A Cause of Donor-Specific Anti-HLA Antibody Formation in Children.

Authors:  Gulsah Kaya Aksoy; Elif Comak; Mustafa Koyun; Halide Akbaş; Bahar Akkaya; Bülent Aydınlı; Fahri Uçar; Sema Akman
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-02-08       Impact factor: 2.441

2.  Patterns in Tacrolimus Variability and Association with De Novo Donor-Specific Antibody Formation in Pediatric Kidney Transplant Recipients.

Authors:  Kim H Piburn; Vaka K Sigurjonsdottir; Olafur S Indridason; Lynn Maestretti; Mary Victoria Patton; Anne McGrath; Runolfur Palsson; Amy Gallo; Abanti Chaudhuri; Paul C Grimm
Journal:  Clin J Am Soc Nephrol       Date:  2022-07-26       Impact factor: 10.614

3.  Pathophysiological Implications of Variability in Blood Tacrolimus Levels in Pediatric and Adolescent Kidney Transplant Recipients.

Authors:  Rachel Becker-Cohen
Journal:  Clin J Am Soc Nephrol       Date:  2022-07-26       Impact factor: 10.614

4.  Combined Analysis of HLA Class II Eplet Mismatch and Tacrolimus Levels for the Prediction of De Novo Donor Specific Antibody Development in Kidney Transplant Recipients.

Authors:  Hyeyoung Lee; Ji Won Min; Hyunhye Kang; Hanbi Lee; Sang Hun Eum; Yohan Park; Chul Woo Yang; Byung Ha Chung; Eun-Jee Oh
Journal:  Int J Mol Sci       Date:  2022-07-01       Impact factor: 6.208

5.  Etiologies and Outcomes Associated With Tacrolimus Levels Out of a Typical Range That Lead to High Variability in Kidney Transplant Recipients.

Authors:  David J Taber; Jason Hirsch; Alison Keys; Zemin Su; John W McGillicuddy
Journal:  Ther Drug Monit       Date:  2021-06-01       Impact factor: 3.118

6.  Association of Intrapatient Variability of Tacrolimus Concentration With Early Deterioration of Chronic Histologic Lesions in Kidney Transplantation.

Authors:  Hyejin Mo; Song-Yi Kim; Sangil Min; Ahram Han; Sanghyun Ahn; Seung-Kee Min; Hajeong Lee; Curie Ahn; Yonsu Kim; Jongwon Ha
Journal:  Transplant Direct       Date:  2019-05-22

7.  Can uric acid blood levels in renal transplant recipients predict allograft outcome?

Authors:  Ofer Isakov; Bhanu K Patibandla; Doron Shwartz; Eytan Mor; Kenneth B Christopher; Tammy Hod
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

8.  Intrapatient Variability in Tacrolimus Trough Levels Over 2 Years Affects Long-Term Allograft Outcomes of Kidney Transplantation.

Authors:  Yohan Park; Hanbi Lee; Sang Hun Eum; Hyung Duk Kim; Eun Jeong Ko; Chul Woo Yang; Byung Ha Chung
Journal:  Front Immunol       Date:  2021-09-30       Impact factor: 7.561

9.  Association of intraindividual tacrolimus variability with de novo donor-specific HLA antibody development and allograft rejection in pediatric kidney transplant recipients with low immunological risk.

Authors:  Maral Baghai Arassi; Laura Gauche; Jeremy Schmidt; Britta Höcker; Susanne Rieger; Caner Süsal; Burkhard Tönshoff; Alexander Fichtner
Journal:  Pediatr Nephrol       Date:  2022-02-15       Impact factor: 3.651

Review 10.  BK Polyomavirus Nephropathy in Kidney Transplantation: Balancing Rejection and Infection.

Authors:  Chia-Lin Shen; Bo-Sheng Wu; Tse-Jen Lien; An-Hang Yang; Chih-Yu Yang
Journal:  Viruses       Date:  2021-03-16       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.